Purpose: This study examined the usefulness of positron emission tomography (PET)/computed tomography (CT) in the diagnosis of metastasis in patients with urothelial carcinoma. Materials and methods: The subjects were patients who were newly diagnosed with urothelial carcinoma in our department on whom we performed CT and PET/CT to search for metastasis. Results: The median age of the 92 subjects was 71 years, and bladder and upper tract urothelial cancer were underlying diseases in 41 (46%) and 51 (54%) patients, respectively. In 66 (72%) of the 92 cases, no metastasis was observed by CT, while PET/CT revealed metastasis in 9 (14%). The 57 (86%) patients in whom both CT and PET/CT showed no metastasis underwent radical surgery, while 2 patients (4%) exhibited pathological lymph node metastasis. Of the 26 patients in whom CT revealed metastasis, PET/CT showed no metastasis in 3 (12%), and the absence of pathological metastasis was confirmed in all patients. Of the 23 patients found to have metastasis in both CT and PET/CT, metastasis that could not be identified by CT was discovered by performing PET/CT in 10 (43%) patients. PET/CT showed significantly higher diagnostic accuracy than CT alone (P < 0.01), with sensitivities of 94.1% and 67.6%, specificities of 100% and 94.8%, and accuracy rates of 97.8% and 84.7%, respectively. Conclusions: PET/CT of patients with urothelial cancer revealed that metastases that cannot be diagnosed by CT alone are found at a significant frequency. Since these metastases can affect treatment choices in patients with urothelial cancer, PET/CT is considered to be useful in diagnosing metastases in patients with urothelial cancer.
Stein JP, Lieskovsky G, Cote R, et al., 2001, Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. J Clin Oncol, 2001(19): 666–675.
Margulis V, Shariat SF, Matin SF, et al., 2009, The Upper Tract Urothelial Carcinoma C: Outcomes of Radical Nephroureterectomy: A Series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009(115): 1224–1233.
Hirobe M, Tanaka T, Shindo T, et al., 2018, Complications Within 90 Days After Radical Cystectomy for Bladder Cancer: Results of a Multicenter Prospective Study in Japan. Int J Clin Oncol, 2018(23): 734–741.
Goodfellow H, Viney Z, Hughes P, et al., 2014, Role of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) -Computed Tomography (CT) in the Staging of Bladder Cancer. BJU Int, 2014(114): 389–395.
Swinnen G, Maes A, Pottel H, et al., 2010, FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. Eur Urol, 2010(57): 641–647.
Vind-Kezunovic S, Bouchelouche K, Ipsen P, et al., 2019, Detection of Lymph Node Metastasis in Patients with Bladder Cancer Using Maximum Standardised Uptake Value and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-Volume Centre Including Long-Term Follow-Up. Eur Urol Focus, 2019(5): 90–96.
Minamoto R, Tateishi T, Inoue T, 2010, Uroepithelial Carcinoma and PET Surgery. Clinical Urology, 2010(64): 1009–1015.
Mertens LS, Fioole-Bruining A, Vegt E, et al., 2013, Impact of (18)F-Fluorodeoxyglucose (FDG) -Positron-Emission Tomography/Computed Tomography (PET/CT) on Management of Patients with Carcinoma Invading Bladder Muscle. BJU Int, 2013(112): 729–734.
Kanda Y, 2012, Investigation of the Freely Available Easy-to-Use Software ?EZR? for Medical Statistics. Bone Marrow Transplantation, 2012(48): 452–458.
Scolieri MJ, Paik ML, Brown SL, et al., 2000, Limitations of Computed Tomography in the Preoperative Staging of Upper Tract Urothelial Carcinoma. Urology, 2000(56): 930–934.
Tanaka H, Yoshida S, Komai Y, et al., 2016, Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management. Urol Int, 2016(96): 65–72.
Girard A, Rouanne M, Taconet S, et al., 2019, Integrated Analysis of (18)F-FDG PET/CT Improves Preoperative Lymph Node Staging for Patients with Invasive Bladder Cancer. Eur Radiol, 2019(29): 4286–4293.